1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. SUPRIYA LIFESCIENCE LTD.
Supriya Lifescience Ltd.
NSE: SUPRIYA | BSE: 543434

Supriya Lifescience Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutSupriya Lifescience Ltd. is an Indian pharmaceutical company primarily engaged in the manufacturing and export of Active Pharmaceutical Ingredients (APIs). Established as a partnership in 1987 and incorporated as a public limited company in 2008, the... Read More
Ask AI about Supriya Lifescience
847.30-22.00(-2.53%)

55.33% Gain from 52W Low

98,126
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Supriya Lifescience is on 06 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
46.6 / 100
Mid-range PerformerThese stocks have average quality, financial and technical momentum, indicating a mid range performerView SimilarEmbed DVM
Analyst Price Target
-

7

S

8

W

1

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

11Positive12Negative

47.8%Pass in checklist

045
55
100

Check P/E Buy Sell Zone

Strong Sell Zone

88.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Supriya Lifescience Stock Price Analysis

Day Price Range

-2.5% 1 Day return
847.3 (LTP)
841.8880.4
LowHigh

Week Price Range

3.5% 1 Week return
847.3 (LTP)
807.2880.4
LowHigh

Month Price Range

-10.8% 1 Month return
847.3 (LTP)
801948.2
LowHigh

52 Week Price Range

9.1% 1 Year return
847.3 (LTP)
545.51,085
LowHigh
View full Price History/Seasonality

Supriya Lifescience Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Supriya Lifescience's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
26
AVG. ESTIMATE
29.5
LOW ESTIMATE
29.5
HIGH ESTIMATE
29.5
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 13.5% in FY27

Consensus Recommendation

2 ANALYST Recommendations
BUY

The consensus recommendation from 2 analysts for Supriya Lifescience is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Supriya Lifescience Technical Analysis

Supriya Lifescience EMA & SMA

Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
5 Day853.3
10 Day856.3
12 Day858.8
20 Day868.0
26 Day872.0
50 Day874.3
100 Day856.3
200 Day814.1

Supriya Lifescience Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202649.0%
Week42.0%
Month43.8%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Supriya Lifescience Resistance and Support

856.52
Pivot
First Resistance871.2
Second Resistance895.2
Third Resistance909.9
First Support832.6
Second Support817.9
Third Support793.9
Day RSI44.2
Day MACD-13.1
Day MFI60.1
Day MACD Signal Line-11.4

Supriya Lifescience Beta

1 Month0.9
1 Year0.7
3 Month1.1
3 Year1.2

Supriya Lifescience Price Change Analysis

↓-10.8%
Over 1 Month
LowHigh
801948.3
↓-2.3%
Over 3 Months
LowHigh
740.51019.8
↑21.9%
Over 6 Months
LowHigh
6661085
↑9.1%
Over 1 Year
LowHigh
545.51085
All Technicals →

Supriya Lifescience Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Satish Waman WaghPromoter54,441,20567.6 %
Cohesion Mk Best Ideas Sub-TrustFii2,550,9393.2 %
HufPublic527,3750.7 %
Aditya Birla Sun Life Insurance Company LimitedDii1,740,3242.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Supriya Lifescience Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GRAVITON RESEARCH CAPITAL LLPBulkSell22 Nov 2024785.02585,068NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase22 Nov 2024784.79585,068NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell12 Aug 2024488.61658,285NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase12 Aug 2024488.59658,285NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell08 Feb 2024342.32627,793NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase08 Feb 2024342.21627,793NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell26 Dec 2023312.40456,665NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase26 Dec 2023312.26456,665NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell12 May 2023248.48403,147NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase12 May 2023248.38403,147NSE
All deals
All insider trades

Supriya Lifescience Corporate Actions

Supriya Lifescience Dividend history and yield

Supriya Lifescience dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Supriya Lifescience dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
104 Sep 2026
1FINAL04 Sep 2026Equity Share
204 Sep 2025
1FINAL05 Sep 2025Equity Share
320 Sep 2024
0.8FINAL-Equity Share
415 Sep 2023
0.6FINAL-Equity Share
501 Sep 2022
0.6FINAL-Equity Share

Supriya Lifescience Board Meetings

Supriya Lifescience past and upcoming board meetings.

#Ex-Date
PurposeNotes
106 Nov 2026
Quarterly Results-
213 Aug 2026
Quarterly Results-
327 May 2026
Audited Results & Final Dividend-
409 Feb 2026
Quarterly Results-
512 Nov 2025
Quarterly Results-
All Corporate Actions

Supriya Lifescience Research Reports

Supriya Lifescience research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
116 Aug 2026Deven Choksey841791.65Accumulate6.23%7.03%pdf
208 Jun 2026Deven Choksey
Target
1049919.1Accumulate14.13%-7.81%pdf
317 Nov 2025Deven Choksey
Reco
Target
850787.35Accumulate7.96%7.61%pdf
421 Aug 2025Deven Choksey800695.1Buy15.09%21.9%pdf
521 Dec 2023SBI Securities309297.05Accumulate4.02%185.24%pdf
All Reports of Supriya

Supriya Lifescience Corporate Filings

Supriya Lifescience BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
31 Oct 2026
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed herewith is the intimation of Results Earnings Call.
PDF
30 Oct 2026
Supriya Lifescience Ltd - 543434 - Board Meeting Intimation for Quarter And Half Year Ended September 30, 2026
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this to inform you that a meeting of the Board of Directors of the Company will be held on Friday, November 06, 2026, inter alia to Consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. This is to further inform you that in accordance with the Company's Code of Conduct for Prevention of Insider Trading, the ''Trading Window' for dealing in securities of the Company by Designated Persons and their immediate relatives is closed from October 1, 2026, till 48 hours after declaration of Unaudited Financial Results on November 06, 2026.
PDF
19 Oct 2026
Supriya Lifescience Ltd - 543434 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.
PDF
13 Oct 2026
Supriya Lifescience Ltd - 543434 - Announcement On ESG Ratings
Please find enclosed
PDF
12 Oct 2026
Supriya Lifescience Ltd - 543434 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, is enclosed herewith. Kindly take the same on record.
PDF
VIEW ALL

Supriya Lifescience DocumentsAsk MarketMind AI

Supriya Lifescience Earnings Call

Supriya Lifescience earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
18 Aug 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
02 Jun 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
17 Feb 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
18 Nov 2025Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
19 Aug 2025Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Supriya Lifescience Annual Reports

Supriya Lifescience financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Supriya Lifescience Credit Ratings

Supriya Lifescience credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
05 Mar 2026icra ratingsSupriya Lifescience Ltd.Ratings WithdrawnLink
29 Dec 2025india ratingsIndia Ratings Assigns Supriya Lifescience’s Bank Loan Facilities ‘IND A+’/PositiveLink
05 Feb 2025icra ratingsSupriya Lifescience Ltd.Ratings reaffirmed; rated amount enhanced and outlook revised to PositiveLink
09 Nov 2023icra ratingsSupriya Lifescience Ltd.Supriya Lifescience Ltd.: Ratings reaffirmed; rated amount enhancedLink
25 Sep 2022icra ratingsSupriya Lifescience Ltd.Supriya Lifescience Ltd.: Ratings upgraded to [ICRA]A(Stable)/[ICRA]A1Link

Supriya Lifescience Investor Presentations

Supriya Lifescience investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
13 Aug 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
27 May 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
09 Feb 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
04 Feb 2026Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationLink
12 Nov 2025Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Supriya Lifescience - Company Profile

Supriya Lifescience Management Structure

Supriya Lifescience management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Dr. Shekhar Bhaskar BhirudPresident(Business Development,Strategy,R & D)-Mar 26
Dr. Prashant Baban ZateVice President(QA/QC)-Mar 26
Mr. Krishna RaghunathanChief Financial Officer-Mar 26
Prachi SatheCompany Secretary,Compliance Officer-Mar 26
Dr. Sushanta Kumar Gouranga MishraChief Scientific Officer-Mar 26

Supriya Lifescience Board of Directors

Supriya Lifescience Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Satish Waman WaghChairman / Executive Director / Managing Director1160.8Mar 25
Saloni Satish WaghE D & Wholetime Director247.5Mar 25
Shivani Satish WaghE D & Wholetime Director247.5Mar 25
Smita Satish WaghE D & Wholetime Director169.4Mar 25
Balasaheb G. SawantE D & Wholetime Director72.8Mar 25
Prachi SatheCompany Sec. & Compli. Officer10Mar 25
Dinesh N ModiIndependent Non Exe. Director3.2Mar 25
Dileep Kumar JainIndependent Non Exe. Director2.5Mar 25
Neelam Yashpal AroraIndependent Non Exe. Director2Mar 25
Ganapati D YadavIndependent Non Exe. Director0.4Mar 25
Sunil Subhash BhagwatIndependent Non Exe. Director0.4Mar 25
MANISH ISHWARLAL PANCHALAdditional Independent Director-Mar 25
Kothandaraman HariAdditional Independent Director-Mar 25
Website: www.supriyalifescience.com

About the company - Business Profile

Supriya Lifescience Ltd. is an Indian pharmaceutical company primarily engaged in the manufacturing and export of Active Pharmaceutical Ingredients (APIs). Established as a partnership in 1987 and incorporated as a public limited company in 2008, the company has developed into a niche player in therapeutic segments including anti-histamines, analgesics, anesthetics, vitamins, anti-asthmatics, and anti-allergics. Headquartered in Mumbai, it maintains a significant global footprint, exporting to over 120 countries. The company operates a backward-integrated business model, supported by a specialized manufacturing facility and dedicated research and development capabilities, positioning it as a key supplier in the global regulated lifescience space.

Key Points

  • Key Facts: Founded in 1987; Headquartered in Mumbai, Maharashtra; Stock Listing: BSE and NSE (listed in 2021).
  • Operations and Resources: The company operates a manufacturing facility in Lote Parshuram, Maharashtra, spanning 33,000 sq. mts. with a reactor capacity of 932 KLPD. The facility features five therapy-based blocks and has received multiple approvals from global regulatory bodies including the USFDA (three times), EDQM, and Health Canada.
  • Market Significance: Supriya Lifescience serves more than 1,500 customers globally. It is a leading exporter, with 85% of its FY25 revenue derived from international markets. The company holds a dominant position in several niche APIs, such as Chlorpheniramine Maleate and Ketamine Hydrochloride.
  • Revenue Breakdown (FY25 Annual):
    • Total Income: ₹7,063 million.
    • EBITDA: ₹2,608 million.
    • Profit After Tax (PAT): ₹1,880 million.
    • Geographical Mix (H1 FY26): Asia (36%), Europe (33%), LATAM (19%), North America (4%), and others (8%).
  • Therapeutic Segment Revenue (H1 FY26):
    • Anesthetic: 54%
    • Anti-Histamine: 12%
    • Analgesic: 12%
    • Vitamins: 10%
    • Anti-Asthmatic: 7%
    • Anti-Allergic: 3%
  • Business Model and Strengths: The company focuses on a backward-integrated model for its core products, ensuring supply chain reliability and cost efficiency. It excels in complex chemical processes and maintains high quality standards, as evidenced by its various international accreditations (WHO-GMP, ISO, CEP).
  • Key Products and Technology: The product basket includes over 40 APIs. Recent advancements include the entry into liquid anesthesia and the commissioning of a new R&D lab at Lote Parshuram (800 sqm) equipped with 20 fume hoods.
  • Hiring and Employees: As of March 31, 2024, the average employee age was 33.49 years. Approximately 82% of the workforce holds technical or professional degrees. The company reported that 26% of its employees had been with the firm for five years or more.
  • Strategic Initiatives:
    • Expansion: Development of "Module E" to further increase production capacity.
    • R&D Focus: Two new R&D centers are being established to drive innovation and product development.
    • Revenue Target: The company has set a target to achieve ₹1,000 crore in revenue by FY27.
    • Partnerships: Secured a CMO project with a leading European company to act as the exclusive API supplier.

References

  1. Annual Report Mar 2025
  2. Investor Presentation Nov 2025
  3. Investor Presentation Feb 2026
  4. Annual Report May 2024

Supriya Lifescience FAQ

Supriya Lifescience today is trading in the red, down by 2.53% at ₹847.3.
Supriya Lifescience is currently trading down 2.53% on an intraday basis. In the past week the stock rose 3.51%. Stock has been down 2.27% in the past quarter and rose 9.06% in the past year. You can view this in the share price history/seasonality section.
Supriya Lifescience is listed on NSE with the ticker SUPRIYA and on BSE as 543434. It's currently trading on NSE at a share price of ₹847.3 and on BSE with a share price of ₹853.3.
The market cap of Supriya Lifescience is ₹6,819.31 Cr. as of Oct 30, 2026.
Supriya Lifescience announced a FINAL dividend of 50% which equals ₹1 in Sep 04, 2026.The last three ex-dates for Supriya Lifescience were Sep 04, 2025, Sep 20, 2024 and Sep 15, 2023. To view the full dividend history of Supriya Lifescience click here.
Supriya Lifescience has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Supriya Lifescience reported ₹192.4 Cr. in revenue, ₹24.04 Cr. in net profit, and ₹50.11 Cr. in EBITD as of Aug 13, 2026 for Q1 FY26-27.
According to the predictions of 2 analysts, the share price prediction for Supriya Lifescience is ₹940 with an upside of 11%.
The PE ratio of Supriya Lifescience is 34.38 as of Oct 30, 2026.
The PB ratio of Supriya Lifescience is 5.58 as of Oct 30, 2026.
You can view the latest analyst reports on the Supriya Lifescience reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×